HRTS Tema GLP-1, Obesity & Cardiometabolic ETF
- 29.760
- +0.120+0.40%
Musk Tests Mounjaro, Ozempic, Wegovy: Which Weight-Loss Drug Won Him Over?
马斯克自曝转用礼来减肥药：效果优于诺和诺德竞品，副作用更少
10 Health Care Stocks With Whale Alerts In Today's Session
Elon Musk Says He Prefers Lilly's Mounjaro Over Novo's Ozempic
参加者限られるなか輸出株が相場をけん引
Eli Lilly's Weight Loss Med Tirzepatide Gets Endorsement From U.K.'s NICE
How Is The Market Feeling About Alnylam Pharmaceuticals?
Biggest Stock Movers Tuesday: X, CYTK, and More
米ハイテク株高の影響は限られバリュー株にシフトする展開
Ely Lilly Shares Are Trading Higher After the FDA Approved the Company's Zepbound, a Weight Loss Drug Designed to Treat Moderate-to-severe Obstructive Sleep Apnea in Adults With Obesity.
Eli Lilly Stock Is Rising Monday: What's Going On?
Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst
Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday
ResMed, Inspire Medical Fall After Lilly's Zepbound Gains Sleep Apnea Indication
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio?
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
Trending Stocks in Bearish Pre-holiday Week for U.S. Stock Market